Skip to main content
. 2004 Aug 5;63(12):1664–1669. doi: 10.1136/ard.2003.012450

Figure 2.

Figure 2

 (A, B, C) Clinical and laboratory data (mean) of the patients with SpA and CD at baseline and during treatment with infliximab or various other conventional treatments (baseline, 45 days, 3, 6, 12, 18 months). The values of CDAI are split into two additional groups: patients with active or inactive CD at baseline.